← Back to Clinical Trials
Recruiting NCT06026735

Non-small Cell Lung Cancer With Central Nervous System Metastasis

Trial Parameters

Condition Lung Cancer With Central Nervous System Metastasis
Sponsor National Taiwan University Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 30
Sex ALL
Min Age 20 Years
Max Age 90 Years
Start Date 2023-01-13
Completion 2027-12
Interventions
lung cancer with brain /leptomeningeal metastasis

Brief Summary

Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.

Eligibility Criteria

Inclusion Criteria: \- A. Non-small cell lung cancer patients diagnosed with brain metastases or meningeal metastases on brain computed tomography (CT) or magnetic resonance (MRI) images. B. Patients with non-small cell lung cancer who are about to undergo surgical brain surgery, such as brain tumor resection, lumbar abdominal drainage, Euclidean storage, or ventriculoperitoneal drainage. Exclusion Criteria: \- A. Non-small cell lung cancer patients without brain metastases or meningeal metastases. B. Physical condition does not allow surgical removal of the tumor.

Related Trials